Media Room

25.03.2020

Phase III Ophthalmology Study (Glaucoma, Ocular Hypertension)

The multicenter, randomized, double-blind, investigator-masked, placebo-controlled phase III study will run in two parallel groups. The primary goal is to evaluate the efficacy of the study medicine against that of the active competitor. The recruitment target for the study is 400 male and female patients aged 18 to 65 with glaucoma or ocular hypertension.